Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 32.00 GBp
Change Today 0.00 / 0.00%
Volume 11.5K
SNG On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

synairgen plc (SNG) Snapshot

Open
32.00 GBp
Previous Close
32.00 GBp
Day High
32.00 GBp
Day Low
32.00 GBp
52 Week High
09/3/14 - 49.50 GBp
52 Week Low
02/16/15 - 26.50 GBp
Market Cap
29.2M
Average Volume 10 Days
20.5K
EPS TTM
0.02 GBp
Shares Outstanding
91.3M
EX-Date
--
P/E TM
18.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNAIRGEN PLC (SNG)

Related News

No related news articles were found.

synairgen plc (SNG) Related Businessweek News

No Related Businessweek News Found

synairgen plc (SNG) Details

Synairgen plc discovers and develops respiratory drugs in the United Kingdom. It develops inhaled interferon beta (IFN-ß) programs comprising IFN-ß in Asthma, a program that is in Phase II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; and IFN-ß in chronic obstructive pulmonary disease (COPD), a program, which has completed Phase I clinical trials used for the treatment or prevention of COPD exacerbations caused by the common cold. The interferon beta is a natural protein found in the body that helps to regulate the immune system and fight off viruses. The company has research collaboration with Pharmaxis Ltd. to develop a selective inhibitor to the lysyl oxidase type 2 enzyme to treat idiopathic pulmonary fibrosis, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

13 Employees
Last Reported Date: 04/23/15
Founded in 2004

synairgen plc (SNG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 394.0K GBP
Finance Director, Company Secretary and Execu...
Total Annual Compensation: 357.0K GBP
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: 294.0K GBP
Compensation as of Fiscal Year 2014.

synairgen plc (SNG) Key Developments

Synairgen plc and Pharmaxis Ltd Enter into Research Collaboration to Develop Selective Inhibitor to the Lysyl Oxidase Type 2

Synairgen plc and Pharmaxis Ltd. announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages the lungs of IPF patients. It is hoped that the inhibition of LOXL2 will slow the build-up of scar tissue and improve survival rates that are worse than for many cancers.

Synairgen, Annual General Meeting, Jun 22, 2015

Synairgen, Annual General Meeting, Jun 22, 2015., at 11:00 GMT Standard Time. Location: at the offices of Fasken Martineau LLP.

Synairgen Reports Unaudited Consolidated Earnings Results for the Full Year Ended December 31, 2014

Synairgen reported unaudited consolidated earnings results for the full year ended December 31, 2014. For the year, revenue was £4,290,000. Profit from operations was £1,094,000 against loss from operations of £2,278,000 a year ago. Profit before tax was £1,125,000 against loss before tax of £2,267,000 a year ago. Profit and total comprehensive income for the period attributable to equity holders of the parent was £1,188,000 against loss and total comprehensive loss for the period attributable to equity holders of the parent of £2,043,000 a year ago, driven by initial receipt from AstraZeneca of £7.25 million received in June 2014. Diluted earnings per share were 1.35 pence against 2.72 pence a year ago. Net cash generated from operating activities was £1,803,000 against net cash used in operating activities of £1,791,000 a year ago. Purchase of property, plant and equipment was £14,000 against £3,000 a year ago. Purchase of intangible assets was £4,000 against £16,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNG:LN 32.00 GBp 0.00

SNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNG.
View Industry Companies
 

Industry Analysis

SNG

Industry Average

Valuation SNG Industry Range
Price/Earnings 23.3x
Price/Sales 6.6x
Price/Book 3.0x
Price/Cash Flow 24.2x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAIRGEN PLC, please visit www.synairgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.